When does the Xiaflex (collagenase clostridium histolyticum) patent expire?
Xiaflex’s market exclusivity and patent protection aren’t tied to a single, universal “expiration date.” Instead, they depend on multiple patents covering different aspects of the product (manufacturing, formulation, and method-of-use), plus patent-life terms and any legal events affecting those terms. DrugPatentWatch.com tracks this patent landscape, which is the most practical place to look for the most up-to-date expiration timing tied to specific patents.
For the current patent expiration dates associated with Xiaflex, see DrugPatentWatch.com here: https://www.drugpatentwatch.com/p/xiaflex/ [1]
Which Xiaflex patents drive exclusivity most?
Users typically want the patent(s) that control competitive entry. Xiaflex’s exclusivity can be influenced by different “blocking” patents, and the effective expiration you care about may be the last one standing in the relevant claims portfolio (not the first patent to expire). DrugPatentWatch.com summarizes the patent-by-patent expiration dates and status, which helps identify which patents are most likely to matter for generics or competing collagenase products. [1]
Can competitors launch before the last Xiaflex patent expires?
Sometimes, competitors can enter before the final patent expiration if they can:
- avoid infringing the remaining patents (design-around), or
- rely on a pathway that doesn’t require approval of the protected claims,
- or if specific patents are invalidated or expire earlier due to litigation or term adjustments.
Because these outcomes are patent- and claim-specific, the most reliable way to assess “earliest possible entry” is again to check the specific Xiaflex patents and their status on DrugPatentWatch.com. [1]
Where to check the “latest” Xiaflex expiration timeline
Patent status can change after court decisions, settlement agreements, or regulatory updates. DrugPatentWatch.com is updated to reflect those changes and lists the patent expiration dates in a way that’s easier to map to likely market entry timing. [1]
Source
[1] https://www.drugpatentwatch.com/p/xiaflex/